R
Rebus Biosystems
A venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise
About Rebus Biosystems
Rebus Biosystems is a Silicon Valley-based life science technology company that specializes in creating advanced tools for spatial omics research. The company's flagship product, the Rebus Esper, is an automated, fully integrated spatial omics platform that provides high-resolution, quantitative single molecule data while maintaining the spatial context of cells. This technology is particularly valuable for researchers studying complex biological systems, such as brain development, by enabling them to obtain high-sensitivity data from hundreds of thousands of cells in a single experiment. Rebus Biosystems primarily serves academic and industrial researchers in the life sciences sector who require precise and comprehensive data for their studies. The company operates in the rapidly growing market of spatial omics, which combines spatial information with molecular data to provide a more detailed understanding of biological processes. Rebus Biosystems generates revenue through the sale of its Rebus Esper platform and associated consumables, as well as through service contracts and support agreements. The business model focuses on providing a streamlined, end-to-end solution that minimizes hands-on time for users, making advanced spatial omics research more accessible and efficient.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Santa Clara, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 28.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Biotechnology, Biotech and Pharma, Techbio, CompBio, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2022 | $32M | $129M | Undisclosed | ↗ |
| SERIES BOther financing | Nov 2020 | $20M | $80M | NCore Ventures · Labgenomics · Timefolio Asset Management · Illumina Ventures | — |
Growth signals
Latest recorded traffic for Rebus Biosystems is 180 monthly website visits, down 79.3% over the last three months. Rebus Biosystems's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Illumina Ventures- NVNCore Ventures
Labgenomics- TMTimefolio Asset Management
Seegene- XIXolon Invest
CTK Investments
Ray Medical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rebus Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rebus Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







